L.N. 5 of 2025

Pharmacy and Poisons (Amendment) Regulation 2025

(Made by the Pharmacy and Poisons Board under section 29(1B) of the Pharmacy and Poisons Ordinance (Cap. 138) subject to the approval of the Secretary for Health)

1. Commencement

(1) Subject to subsection (2), this Regulation comes into operation on the day on which it is published in the Gazette.

(2) Sections 3(5), 4(5) and 5(5) come into operation on the expiry of 6 months beginning on the day on which this Regulation is published in the Gazette.

2. Pharmacy and Poisons Regulations amended

The Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) are amended as set out in sections 3, 4 and 5.

3. Schedule 1 amended (substances to which certain restrictions with respect to the sale, supply, labelling and storage apply under regulations 3, 5, 6, 22 and 24)

(1) Schedule 1, Division A, before item "Binimetinib; its salts"—

Add

"Bimekizumab".

(2) Schedule 1, Division A, after item "Delamanid; its salts"—

Add

"Delandistrogene moxeparvovec".

(3) Schedule 1, Division A, before item "Filgotinib; its salts"—

Add

"Fezolinetant; its salts".

(4) Schedule 1, Division A, after item "Marbofloxacin; its salts"—

Add

"Maribavir; its salts".

(5) Schedule 1, Division A, after item "Nicocodine; its salts"—

Add

"Nicotinamide mononucleotide when contained as an active ingredient in products for human parenteral administration".

(6) Schedule 1, Division A, before item "Rabeprazole; its salts"—

Add

"Quizartinib; its salts".

(7) Schedule 1, Division A, after item "Tapentadol; its salts"—

Add

"Tarlatamab".

4. Schedule 3 amended (substances required by regulation 9 to be sold by retail only upon a prescription given by a registered medical practitioner, registered dentist or registered veterinary surgeon)

(1) Schedule 3, Division A, before item "Binimetinib; its salts"—

Add

"Bimekizumab".

(2) Schedule 3, Division A, after item "Delamanid; its salts"—

Add

"Delandistrogene moxeparvovec".

(3) Schedule 3, Division A, before item "Filgotinib; its salts"—

Add

"Fezolinetant; its salts".

(4) Schedule 3, Division A, after item "Marbofloxacin; its salts"—

Add

"Maribavir; its salts".

(5) Schedule 3, Division A, after item "Nicocodine; its salts"—

Add

"Nicotinamide mononucleotide when contained as an active ingredient in products for human parenteral administration".

(6) Schedule 3, Division A, before item "Rabeprazole; its salts"—

Add

"Quizartinib; its salts".

(7) Schedule 3, Division A, after item "Tapentadol; its salts"—

Add

"Tarlatamab".

5. Schedule 10 amended (Poisons List)

(1) Schedule 10, section 2, Table, Part 1, Division A, before item "Binimetinib; its salts"—

Add

"Bimekizumab".

(2) Schedule 10, section 2, Table, Part 1, Division A, after item "Delamanid; its salts"—

Add

"Delandistrogene moxeparvovec".

(3) Schedule 10, section 2, Table, Part 1, Division A, before item "Filgotinib; its salts"—

Add

"Fezolinetant; its salts".

(4) Schedule 10, section 2, Table, Part 1, Division A, after item "Marbofloxacin; its salts"—

Add

"Maribavir; its salts".

(5) Schedule 10, section 2, Table, Part 1, Division A, after item "Nicocodine; its salts"—

Add

"Nicotinamide mononucleotide when contained as an active ingredient in products for human parenteral administration".

(6) Schedule 10, section 2, Table, Part 1, Division A, before item "Rabeprazole; its salts"—

Add

"Quizartinib; its salts".

(7) Schedule 10, section 2, Table, Part 1, Division A, after item "Tapentadol; its salts"—

Add

"Tarlatamab".

Ronald LAM Man-kin
Chairman,
Pharmacy and Poisons Board

14 January 2025

Explanatory Note

This Regulation amends the Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) to add certain substances (***newly added substances***) to the following provisions—

(a) Division A of Schedule 1;

(b) Division A of Schedule 3;

(c) Division A of Part 1 of the Poisons List set out in Schedule 10.

2. After the amendments take effect—

(a) the sale, by retail, of the newly added substances—

(i) may only be effected on the registered premises of an authorized seller of poisons by a registered pharmacist or in the presence and under the supervision of a registered pharmacist; and

(ii) may only be effected on and in accordance with a prescription by a registered medical practitioner, registered dentist or registered veterinary surgeon; and

(b) the newly added substances, if stored in retail premises, must be stored in a part of the premises to which customers are not permitted access.